HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.

Abstract
Lung and prostate cancers are major health problems worldwide. Treatments with standard chemotherapy agents are relatively ineffective. Combination chemotherapy gives better treatment than a single agent because the drugs can inhibit the cancer in different pathways, but new therapeutic agents are needed for the treatment of both tumor types. Bradykinin (BK) antagonists offer advantages of combination therapy in one compound. These promising multitargeted anti-cancer compounds selectively stimulate apoptosis in cancers and also inhibit both angiogenesis and matrix metalloprotease (MMP) action in treated lung and prostate tumors in nude mice. The highly potent, metabolism-resistant bradykinin antagonist peptide dimer, B-9870 [SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)2] (SUIM=suberimidyl; Hyp=4-hydroxyproline; Igl=alpha-(2-indanyl)glycine; Oic=octahydroindole-2-carboxylic acid) and its non-peptide mimetic, BKM-570 [2,3,4,5,6-pentafluorocinnamoyl-(o-2,6-dichlorobenzyl)-L-tyrosine-N-(4-amino-2,2,6,6-tetramethylpiperidyl)amide] are superior to the widely used but toxic chemotherapeutic drugs cisplatin and taxotere. In certain combinations, they act synergistically with standard anti-cancer drugs. Due to its structure and biological activity, BKM-570 is an attractive lead compound for derivatization and evaluation for lung and prostate cancer drugs.
AuthorsJohn M Stewart, Lajos Gera, Daniel C Chan, Eunice J York, Vitalija Simkeviciene, Paul A Bunn Jr, Laimute Taraseviciene-Stewart
JournalPeptides (Peptides) Vol. 26 Issue 8 Pg. 1288-91 (Aug 2005) ISSN: 0196-9781 [Print] United States
PMID15878795 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • BKM-1174
  • BKM-570
  • CU201
  • Matrix Metalloproteinase Inhibitors
  • Oligopeptides
  • Tyrosine
  • Phenylalanine
  • Bradykinin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Bradykinin (antagonists & inhibitors)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Drug Screening Assays, Antitumor
  • Guinea Pigs
  • Humans
  • Ileum (drug effects)
  • Matrix Metalloproteinase Inhibitors
  • Mice
  • Mice, Nude
  • Oligopeptides (administration & dosage, chemistry, pharmacology)
  • Phenylalanine (analogs & derivatives, pharmacology)
  • Rabbits
  • Rats
  • Structure-Activity Relationship
  • Tyrosine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: